{"data":{"id":712,"lang":"en","title":"Vertex Kidney Drug Povetacicept Achieves Breakthrough Phase 3 Results, FDA Filing Expected This Month","summary":"Vertex's povetacicept cut proteinuria by 52% in Phase 3 kidney disease trial, with FDA filing expected by end of March.","category":"science","category_label":"Science","published_at":"2026-03-11T05:02:03Z","updated_at":"2026-03-11T05:02:03Z","url":"https://techtools.cz/tools/news/article/712-vertex-kidney-drug-povetacicept-achieves-breakthrough-phase-3-results-fda","api_url":"https://techtools.cz/news-api/v1/articles/712?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/712.md?lang=en","image_url":"https://imgproxy.divecdn.com/vutd5O0kywAPvKnVvvCJbgnY9GpGFlkNG1Q3kszWIJY/g:ce/rs:fill:1200:1200:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjUtMTAtMDhfYXRfMTAuMDMuMzVfQU0ucG5n.webp","word_count":142,"reading_time_minutes":1,"sources":[{"url":"https://www.biopharmadive.com/news/vertex-povetacicept-iga-nephropathy-study-results/814253/","domain":"biopharmadive.com"},{"url":"https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-week-36-interim-analysis-results","domain":"news.vrtx.com"}],"translation":{"lang":"cs","id":727,"title":"Lék Povetacicept od Vertex dosáhl průlomových výsledků ve studii fáze 3, žádost o schválení FDA očekávána tento měsíc","url":"https://techtools.cz/tools/news/clanek/727-lek-povetacicept-od-vertex-dosahl-prulomovych-vysledku-ve-studii-faze-3-zadost","api_url":"https://techtools.cz/news-api/v1/articles/727?lang=cs"},"content":"Vertex Pharmaceuticals reported landmark Phase 3 results for povetacicept, a dual BAFF/APRIL inhibitor targeting IgA nephropathy, a progressive kidney disease affecting millions worldwide. In the Week 36 interim analysis of the RAINIER trial, patients achieved a 52% reduction in proteinuria from baseline — a 49.8% improvement over placebo (P\u003c0.0001). Vertex shares climbed more than 5% on the news.\n\nSecondary endpoints were equally striking: the drug reduced serum Gd-IgA1 levels by 77.4% and achieved hematuria resolution in 85.1% of treated patients, both with high statistical significance versus placebo.\n\nThe company plans to complete its full BLA submission to the FDA by the end of March, using a priority review voucher to cut the review timeline from ten to six months. If approved, povetacicept would become a first-in-class treatment for IgA nephropathy, a disease with limited options that can progress to kidney failure."}}